Across TCGA pan-cancer cohorts, SMOX Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SMOX data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SMOX Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMOX expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
BLCA, UCEC, and SKCM are the cancer types where SMOX Mutation most reproducibly stratifies survival.